Plazomicin is a next-generation aminoglycoside antibiotic indicated for the treatment of complicated urinary tract infections, typically reserved for cases where other therapeutic options are limited or… Read more








Plazomicin is a next-generation aminoglycoside antibiotic indicated for the treatment of complicated urinary tract infections, typically reserved for cases where other therapeutic options are limited or contraindicated. It functions by inhibiting bacterial protein synthesis to combat susceptible strains of pathogens. To support rigorous quality control and pharmaceutical research, this category provides high-quality reference standards for the Plazomicin active pharmaceutical ingredient (API), alongside a comprehensive selection of process-related impurities and metabolites. These include specific nitroso-related impurities and stable isotope-labelled compounds, such as deuterated analogues, which are essential tools for accurate impurity profiling and method validation. By utilizing these characterized reference materials, laboratories can ensure the precision of analytical testing, enabling the reliable identification and quantification of related substances throughout the drug development and manufacturing lifecycle.